ZYUS Life Sciences Corp
- LAST PRICE1.0500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.0200/ 5
- Ask / Lots1.0500/ 34
- Open / Previous Close0.0000 / 1.0500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ZYUS |
|---|---|---|
| 10:30 ET | 4900 | 1.04 |
| 11:04 ET | 200 | 1.05 |
| 03:12 ET | 1400 | 1.05 |
Today
ZYUS Announces Anticipated Delay in Its Annual Filings, from 45 minutes ago by Dow Jones
45 minutes ago by Dow Jones
Apr 23, 2024
ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management, from 7:00AM ET on Tuesday Apr 23, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ZYUS Life Sciences Corp | 74.4M | -3.6x | --- |
KDA Group Inc | 70.2M | 199.0x | --- |
Briacell Therapeutics Corp | 46.9M | -2.6x | --- |
Nurexone Biologic Inc | 42.8M | -5.8x | --- |
Defence Therapeutics Inc | 56.8M | -4.0x | --- |
Satellos Bioscience Inc | 54.2M | -3.2x | --- |
Company Information
ZYUS Life Sciences Corporation is a Canada-based life sciences company. The Company is focused on the global development and commercialization of cannabinoid-based pharmaceutical drug product candidates and exempt market therapeutics. Through clinical research, it is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, the Company delivers cGMP / EU GMP-compliant cannabinoid products to patients through the exempt global medical market. The Company is also focused on commercialization of its exempt market therapeutics, such as cannabinoid oils, soft gel capsules and topical creams, in Canada and those international markets where medical cannabis is legal.
Contact Information
- Headquarters
- 204 - 407 Downey RoadSASKATOON, SK, Canada S7N 4L8
- Phone
- 306-242-2357
- Fax
- 416-368-4440
Executives
- Chairman of the Board
- Charlotte Hepburn
- President, Chief Executive Officer
- Brent Zettl
- Chief Financial Officer
- Michael Kindy
- Independent Director
- Charles Burns
- Independent Director
- Michael Detlefsen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $74.4M |
|---|---|
Revenue (TTM) | $254.0K |
Shares Outstanding | 70.8M |
ZYUS Life Sciences Corp does not pay a dividend. | |
Beta | --- |
EPS | $-0.29 |
Book Value | $1.62 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | 292.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5,624.24% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
